IL-4 Protein, Human

Catalog Number: UA040026 Reactivity: Human Conjugation: Unconjugated Brand: UA BIOSCIENCE

Price:

$180.00 USD

Size: 10μg 50μg 100μg 500μg 1mg

Quantity:

For shipping services or bulk orders, you may request a quotation.

Secure checkout with

View full details

Product Details

Product Specification

Species	Human
Antigen	IL-4
Accession	P05112
Amino Acid Sequence	His25-Ser153
Expression System	E.coli
Molecular Weight	15-16kDa (Reducing)
Purity	＞95% by SDS-PAGE
Endotoxin	<0.1EU/μg
Conjugation	Unconjugated
Tag	No Tag
Physical Appearance	Lyophilized Powder
Storage Buffer	20mM Tris, 150mM NaCl, 1mM EDTA, pH8.0
Reconstitution	Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
Stability & Storage	· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles.

Background

Interleukin 4(IL4) was first identified as a helper T cell product with the capacity to co-stimulate B cell growth in vitro. IL-4 also can rescue B-cells from apoptosis, enhancing their survival, and is responsible for immunoglobulin isotype switching to IgG1 and IgE. The effect of IL-4 signaling is mediated through the IL-4 receptor alpha chain (IL-4Rα). Upon binding to its ligand, IL-4Rα dimerizes either with the common gamma chain (γc) to produce the type-1 signaling complex located mainly on hematopoietic cells, or with the IL-13 receptor alpha 1 (IL-13Rα1) to produce the type-2 complex, which is expressed also on non-hematopoietic cells. The type-1 signaling complex is critical for Th2-skewing of T cells and the development of alternatively activated macrophages (AAMΦs), while the type-2 complex plays a role in non-hematopoietic responses to IL-4 and IL-13.

Picture

Western Blot

Primary antibody: CD209 gamma Recombinant Rabbit mAb (S0B1390) at 1/1000 dilution

Lane 1: untreated THP-1 whole cell lysate 20 µg

Lane 2: THP-1 treated with 100 ng/ml GM-CSF (UA040002) and 50 ng/ml hIL-4 (UA040026) for 7 days whole cell lysate 20 µg

Lane 3: THP-1 treated with 100 ng/ml GM-CSF (Competotor T) and 50 ng/ml hIL-4 (UA040026) for 7 days whole cell lysate 20 µg

Lane 4: THP-1 treated with 100 ng/ml GM-CSF (UA040002) and 50 ng/ml hIL-4 (Competitor P) for 7 days whole cell lysate 20 µg

Lane 5: THP-1 treated with 100 ng/ml GM-CSF (Competotor T) and 50 ng/ml hIL-4 (Competitor P) for 7 days whole cell lysate 20 µg

Secondary antibody: Goat Anti-rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution

Predicted MW: 46 kDa

Observed MW: 45~55 kDa

Bioactivity

Measured in a cell proliferation assay using TF-1 human erythroleukemic cells, the EC50 for this effect is less than 0.2ng/ml.

Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The EC50 for this effect is less than 0.2ng/ml.

SDS-PAGE

1μg (R: reducing condition, N: non-reducing condition).

ELISA

Immobilized IL-4 Protein, Human (Cat. No. UA040026) at 2.0μg/mL (100μL/well) can bind IL-4R alpha/CD124 Fc Chimera Protein, Cynomolgus (Cat. No. UA010387) with EC50 of 1.97-3.24 ng/mL.

Immobilized IL-4, Human (Cat. No. UA040026) at 2.0μg/mL (100μL/well) can bind IL-4Rα/CD124 His Tag, Cynomolgus (Cat. No. UA010379) with EC50 of 42.22-60.87 ng/mL.

Immobilized IL-4 Protein, Human (Cat. No. UA040026) at 5.0μg/mL (100μL/well) can bind IL-4R alpha/CD124 His Tag Protein, Human (Cat. No. UA010382) with EC50 of 13.41-18.20ng/mL.

Immobilized IL-4 Protein, Human (Cat. No. UA040026) at 5.0μg/mL (100μL/well) can bind Biotinylated IL-4R alpha/CD124 Avi&His Tag Protein, Human (Cat. No. UA010671) with EC50 of 27.67-45.87ng/mL.